TrialCurveAcalabrutinib vs chlorambucil + rituximab in CLL (Asian phase 3): reconstructed Kaplan–Meier curves
Acalabrutinib vs chlorambucil plus rituximab in untreated chronic lymphocytic leukemia: A randomized phase 3 Asian study. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Ann Hematol. 2026 May 19;105(8):327. doi: 10.1007/s00277-026-07006-z |
|---|---|
| DOI | 10.1007/s00277-026-07006-z |
| Registry | NCT04075292 |
| Phase | Phase 3 |
| Conditions | Untreated Chronic Lymphocytic Leukemia |
| Interventions | Acalabrutinib, Rituximab, Chlorambucil |
| Sponsor | AstraZeneca |
| Enrolment | 155 |
| Source licence | Figure published under CC BY 4.0 |
BICR-assessed progression-free survival — Overall cohort
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Acala not reached; C+R 15.5 months. Survival at 12 months: Acala 94%; C+R 59%. Hazard ratio Acala vs C+R 0.08 (95% CI 0.04–0.20).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Acala | 77 | 6 | not reached |
| C+R | 78 | 42 | 15.5 |
- Acala vs C+R: reconstructed HR 0.08 (95% CI 0.04–0.20)
Landmark survival (reconstructed)
| Time | Acala | C+R |
|---|---|---|
| 6 mo | 97.2% | 95.7% |
| 12 mo | 94.2% | 58.6% |
| 18 mo | 94.2% | 36.5% |
| 24 mo | 91.9% | 25.1% |
| 36 mo | 87.3% | 17.6% |
Checks against the published figure
- C+R median: printed 15.5, reconstructed 15.5 pass
- hazard ratio: printed 0.08, reconstructed 0.0833 pass
BICR-assessed progression-free survival — China cohort
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Acala not reached; C+R 14.3 months. Survival at 12 months: Acala 94%; C+R 61%. Hazard ratio Acala vs C+R 0.08 (95% CI 0.03–0.24).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Acala | 53 | 6 | not reached |
| C+R | 50 | 24 | 14.3 |
- Acala vs C+R: reconstructed HR 0.08 (95% CI 0.03–0.24)
Landmark survival (reconstructed)
| Time | Acala | C+R |
|---|---|---|
| 6 mo | 96.0% | 95.5% |
| 12 mo | 94.0% | 61.3% |
| 18 mo | 94.0% | 31.4% |
| 24 mo | 90.0% | — |
| 36 mo | 64.3% | — |
Checks against the published figure
- C+R median: printed 14.4, reconstructed 14.3 pass
- hazard ratio: printed 0.08, reconstructed 0.0822 pass
BICR-assessed duration of response — Overall cohort (responders)
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Acala not reached; C+R 11.5 months. Survival at 12 months: Acala 98%; C+R 49%. Hazard ratio Acala vs C+R 0.05 (95% CI 0.02–0.16).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Acala | 59 | 3 | not reached |
| C+R | 56 | 33 | 11.5 |
- Acala vs C+R: reconstructed HR 0.05 (95% CI 0.02–0.16)
Landmark survival (reconstructed)
| Time | Acala | C+R |
|---|---|---|
| 6 mo | 100.0% | 79.5% |
| 12 mo | 98.0% | 48.8% |
| 18 mo | 94.7% | 32.9% |
| 24 mo | 88.7% | 25.9% |
| 36 mo | — | — |
Checks against the published figure
- C+R median: printed 11.6, reconstructed 11.5 pass
- hazard ratio: printed 0.05, reconstructed 0.0497 pass
BICR-assessed duration of response — China cohort (responders)
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Acala not reached; C+R 10.9 months. Survival at 12 months: Acala 100%; C+R 33%. Hazard ratio Acala vs C+R 0.02 (95% CI 0.00–0.16).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Acala | 39 | 2 | not reached |
| C+R | 35 | 18 | 10.9 |
- Acala vs C+R: reconstructed HR 0.02 (95% CI 0.00–0.16)
Landmark survival (reconstructed)
| Time | Acala | C+R |
|---|---|---|
| 6 mo | 100.0% | 79.0% |
| 12 mo | 100.0% | 33.2% |
| 18 mo | 94.1% | 22.8% |
| 24 mo | 80.7% | — |
Checks against the published figure
- C+R median: printed 10.9, reconstructed 10.9 pass
- hazard ratio: printed 0.02, reconstructed 0.0213 pass
Time to next treatment — Overall cohort
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Acala not reached; C+R 26.2 months. Survival at 12 months: Acala 93%; C+R 93%. Hazard ratio Acala vs C+R 0.20 (95% CI 0.09–0.44).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Acala | 77 | 8 | not reached |
| C+R | 78 | 30 | 26.2 |
- Acala vs C+R: reconstructed HR 0.20 (95% CI 0.09–0.44)
Landmark survival (reconstructed)
| Time | Acala | C+R |
|---|---|---|
| 6 mo | 96.0% | 97.3% |
| 12 mo | 93.3% | 92.9% |
| 18 mo | 91.7% | 73.4% |
| 24 mo | 89.6% | 51.7% |
| 36 mo | 87.1% | 38.4% |
Checks against the published figure
- C+R median: printed 26.2, reconstructed 26.2 pass
- hazard ratio: printed 0.2, reconstructed 0.2 pass
Time to next treatment — China cohort
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Acala not reached; C+R 23.9 months. Survival at 12 months: Acala 90%; C+R 93%. Hazard ratio Acala vs C+R 0.27 (95% CI 0.10–0.70).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Acala | 53 | 6 | not reached |
| C+R | 50 | 15 | 23.9 |
- Acala vs C+R: reconstructed HR 0.27 (95% CI 0.10–0.70)
Landmark survival (reconstructed)
| Time | Acala | C+R |
|---|---|---|
| 6 mo | 94.3% | 100.0% |
| 12 mo | 90.5% | 92.5% |
| 18 mo | 90.5% | 74.3% |
| 24 mo | 86.8% | 47.6% |
| 36 mo | 86.8% | — |
Checks against the published figure
- C+R median: printed 23.9, reconstructed 23.9 pass
- hazard ratio: printed 0.26, reconstructed 0.269 pass
Overall survival — Overall cohort
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Acala not reached; C+R not reached. Survival at 12 months: Acala 99%; C+R 99%. Hazard ratio Acala vs C+R 0.38 (95% CI 0.07–1.94).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Acala | 77 | 2 | not reached |
| C+R | 78 | 5 | not reached |
- Acala vs C+R: reconstructed HR 0.38 (95% CI 0.07–1.94)
Landmark survival (reconstructed)
| Time | Acala | C+R |
|---|---|---|
| 6 mo | 98.7% | 98.6% |
| 12 mo | 98.7% | 98.6% |
| 18 mo | 97.1% | 96.7% |
| 24 mo | 97.1% | 94.6% |
| 36 mo | 97.1% | 86.1% |
Checks against the published figure
- hazard ratio: printed 0.38, reconstructed 0.377 pass
Overall survival — China cohort
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Acala not reached; C+R not reached. Survival at 12 months: Acala 98%; C+R 100%. Hazard ratio Acala vs C+R 0.82 (95% CI 0.05–13.07).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Acala | 53 | 1 | not reached |
| C+R | 50 | 1 | not reached |
- Acala vs C+R: reconstructed HR 0.82 (95% CI 0.05–13.07)
Landmark survival (reconstructed)
| Time | Acala | C+R |
|---|---|---|
| 6 mo | 98.1% | 100.0% |
| 12 mo | 98.1% | 100.0% |
| 18 mo | 98.1% | 100.0% |
| 24 mo | 98.1% | 95.2% |
| 36 mo | 98.1% | 95.2% |
Checks against the published figure
- hazard ratio: printed 0.83, reconstructed 0.816 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- CPT-MM301: Overall survival; Progression-free survival (Independent Assessment Committee)
- CEPHEUS: Overall survival; Progression-free survival
- Mesenchymal stromal cells for steroid-resistant acute GVHD: Cumulative incidence of leukemia relapse; Non-relapse mortality (NRM); Overall survival; c
- ADMYRE: Overall survival; Progression-free survival with PD confirmation by investigator's assessm
- CLL12: Event-free survival (EFS); Overall survival (OS)
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials